Get the Stockscreener App
1.52
0.98%
-0.01
Erasca Inc stock is traded at $1.52, with a volume of 210.50K.
It is down -0.98% in the last 24 hours and down -7.06% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.53
Open:
$1.54
24h Volume:
210.50K
Relative Volume:
0.16
Market Cap:
$424.09M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.8537
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+6.69%
1M Performance:
-7.06%
6M Performance:
-48.99%
1Y Performance:
-31.76%
1-Day Range:
$1.49
$1.555
1-Week Range:
$1.405
$1.585
52-Week Range:
$1.27
$3.45
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.515 | 424.09M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.81 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.98 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.98 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.67 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.16 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) Price Target at $5.70 - Defense World
Morgan Stanley Reaffirms Overweight Rating for Erasca (NASDAQ:ERAS) - Defense World
Rhumbline Advisers Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge - TipRanks
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by New York State Common Retirement Fund - Defense World
Erasca stock hits 52-week low at $1.32 amid market challenges - Investing.com Australia
Erasca Inc Still Hasn’t Convinced Analysts? - Stocks Register
Erasca stock hits 52-week low at $1.5 amid market challenges By Investing.com - Investing.com South Africa
Erasca stock hits 52-week low at $1.5 amid market challenges - Investing.com India
Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Investor’s Toolkit: Key Ratios for Assessing Erasca Inc (ERAS)’s Performance - The Dwinnex
Erasca Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Erasca Inc [ERAS] Records 200-Day SMA of $2.5522 - Knox Daily
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
BlackBerry Ltd [BB] Records 200-Day SMA of $2.77 - Knox Daily
Erasca (NASDAQ:ERAS) Stock Price Down 6.1%What's Next? - MarketBeat
Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex
Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News
Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Oncology Pioneer Erasca Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha
What Are You Thinking About Investing In Erasca Inc (NASDAQ: ERAS) Stock? - Stocks Register
Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround - MSN
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Stock Price Down 6.2%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Sells 13,100 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by Barclays PLC - Defense World
Erasca Highlights Strategic Focus at Healthcare Conference - TipRanks
Jane Street Group LLC Trims Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Down 8.7%What's Next? - MarketBeat
Erasca (NASDAQ:ERAS) Upgraded at Bank of America - Defense World
Erasca (NASDAQ:ERAS) Shares Up 3%Still a Buy? - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Principal Financial Group Inc. - Defense World
Erasca (NASDAQ:ERAS) Rating Increased to Buy at Bank of America - MarketBeat
Erasca (NASDAQ:ERAS) Shares Gap UpWhat's Next? - MarketBeat
Erasca to Present at J.P. Morgan Healthcare Conference 2025: RAS/MAPK Cancer Innovations - StockTitan
Franklin Resources Inc. Invests $181,000 in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Up 7.6%Should You Buy? - MarketBeat
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):